<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/3.2.1" -->
<!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.2.6" -->
<!-- generated-on="November 2, 2011 7:36 am" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://www.neurim.com/</loc>
		<lastmod>2011-11-02T07:36:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>1.0</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/contact-us/</loc>
		<lastmod>2011-11-02T07:36:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/products/circadin/</loc>
		<lastmod>2011-10-30T08:56:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/partners/</loc>
		<lastmod>2011-10-26T09:23:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/products/circadin/publications/</loc>
		<lastmod>2011-10-04T14:46:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/business/</loc>
		<lastmod>2011-08-14T07:21:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2007-04-26/summary-of-positive-opinion-for-circadin-emea-press-release/</loc>
		<lastmod>2011-07-28T06:40:57+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2007-04-27/circadin-recommended-for-approval-in-the-eu/</loc>
		<lastmod>2011-07-28T06:40:50+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2011-07-24/circadin-demonstrating-maintenance-of-postural-stability/</loc>
		<lastmod>2011-07-28T06:39:20+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2011-07-24/positive-results-from-phase-i-and-ib-clinical-trials-with-neu-p11/</loc>
		<lastmod>2011-07-28T06:39:07+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/products/circadin/ask-a-question/</loc>
		<lastmod>2011-07-13T06:30:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/</loc>
		<lastmod>2011-07-07T11:26:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/research/therapeutic-area/</loc>
		<lastmod>2011-07-07T11:26:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/research/</loc>
		<lastmod>2011-07-07T11:25:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/about/founders/</loc>
		<lastmod>2011-07-07T11:25:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/about/</loc>
		<lastmod>2011-07-07T11:25:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/products/circadin/chronic-insomnia/</loc>
		<lastmod>2011-07-07T11:25:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/products/circadin/insomnia/</loc>
		<lastmod>2011-07-07T11:25:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/products/</loc>
		<lastmod>2011-07-07T11:24:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2010-07-05/circadin-approved-eu-for-up-to-3-months/</loc>
		<lastmod>2011-06-22T13:42:37+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2007-07-06/nycomed-to-market-circadin-for-primary-insomnia/</loc>
		<lastmod>2011-06-20T05:56:30+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/news/2009-06-11/neurim-pharmaceuticals-reports-long-term-efficacy-and-safety-for-circadin-for-insomnia-in-elderly-patients/</loc>
		<lastmod>2011-06-20T05:56:21+00:00</lastmod>
		<changefreq>yearly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/legal/</loc>
		<lastmod>2011-06-12T08:35:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.neurim.com/disclaimer/</loc>
		<lastmod>2011-06-12T08:33:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
</urlset>
